| 孔鑫磊,黄红英,李卫斌,唐万云,刘 波.沙美特罗替卡松联合布地格福吸入气雾剂对支气管哮喘的应用效果及对 Treg T细胞亚群的影响[J].,2024,(9):1783-1786 |
| 沙美特罗替卡松联合布地格福吸入气雾剂对支气管哮喘的应用效果及对 Treg T细胞亚群的影响 |
| Effect of Salmeterol Fluticasone Combined with Budesonide Inhalation Aerosol on Bronchial Asthma and Treg T Cell Subsets |
| 投稿时间：2023-11-05 修订日期：2023-11-27 |
| DOI：10.13241/j.cnki.pmb.2024.09.036 |
| 中文关键词: 沙美特罗替卡松 布地格福吸入气雾剂 支气管哮喘 T细胞亚群 不良反应 |
| 英文关键词: Salmeterol fluticasone Budesonide inhalation aerosol Bronchial asthma T cell subsets Adverse reactions |
| 基金项目:青海省卫生健康委员会指导性计划课题（2022-wjzdx-11） |
|
| 摘要点击次数: 63 |
| 全文下载次数: 47 |
| 中文摘要: |
| 摘要 目的：探讨沙美特罗替卡松联合布地格福吸入气雾剂对支气管哮喘的应用效果及对 Treg T细胞亚群的影响。方法：选2021年6月到2023年4月收治的80例支气管哮喘患者，分为观察组与对照组，各40例。对照组应用沙美特罗替卡松吸入治疗，观察组应用沙美特罗替卡松联合布地格福吸入气雾剂吸入治疗，对比两组患者体征和症状消失时间，治疗前与治疗1个月后肿瘤坏死因子-α（TNF-α）、干扰素-γ（IFN-γ）、白细胞介素-6（Interleukin-4，IL-6）及T细胞亚群表达水平，并对比两组患者不良反应发生率。结果：观察组患者湿啰音消失时间、咳嗽消失时间等体征及症状消失时间较对照组短（P＜0.05）；治疗前，两组患者TNF-α、IFN-γ、IL-6水平对比无差异（P＞0.05），治疗后均降低，且与对照组相比，观察组较低（P＜0.05）；治疗前两组患者CD4+、CD3+和CD4+/CD8+数值对比无差异（P＞0.05），治疗后观察组患者CD4+、CD3+和CD4+/ CD8+数值均升高，且观察组高于对照组（P＜0.05）；两组患者不良反应发生率对比无差异（P＞0.05）。结论：沙美特罗替卡松联合布地格福吸入气雾剂对支气管哮喘的应用效果显著，能够缩短患者症状与体征持续时间，降低机体炎症因子反应，提升T细胞亚群比率，安全性较高。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of salmeterol fluticasone combined with budesonide inhalation aerosol on bronchial asthma and Treg T cell subsets. Methods: Eighty patients with bronchial asthma admitted from June 2021 to April 2023 were selected and divided into observation group and matched group, 40 each. The matched group was treated with salmeterol fluticasone inhalation, and the observation group was treated with salmeterol fluticasone combined with budesonide inhalation aerosol inhalation. The signs and symptoms disappeared time, tumor necrosis factor pretherapy and 1 month post-treatment were compared between the two groups (tumor necrosis factor-α(TNF-α), Interferon-γ (IFN-γ), The expression levels of interleukin-6 (IL-6) and T cell subsets were detected, and the incidence of adverse reactions was compared between the two groups. Results: In the observation group, the disappearance time of wet rales and cough were shorter than that of the matched group (P<0.05); pretherapy, There was no difference in TNF-α, IFN-γ, and IL-6 levels between the two groups (P>0.05), Both were decreased after the treatment, And, when compared with the matched group, The value was lower in the observation group(P<0.05); There was no difference in CD4+, CD3+ and CD4+/CD8+ values between the two previous treatment groups (P>0.05), CD4+, CD3+, and CD4+/CD8+ values were increased in the post / treatment observation group, And the observation group was higher than the matched group (P<0.05); There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: The application effect of salmeterol fluticasone combined with budesonide inhalation aerosol in the treatment of bronchial asthma is significant, which can shorten the duration of symptoms and signs of patients, reduce the reaction of inflammatory factors, and improve the ratio of T cell subsets, with high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
